Publications by authors named "Piotr Szczypa"
Objective: To evaluate longterm drug survival (proportion of patients still receiving treatment) and discontinuation of etanercept (ETN), infliximab (IFX), adalimumab (ADA), certolizumab pegol (CZP), and golimumab (GOL) using observational data from patients with rheumatoid arthritis (RA).
Methods: Following a systematic literature review, drug survival at 12 and 12-24 months of followup was estimated by summing proportions of patients continuing treatment and dividing by number of studies. Drug survival at ≥ 36 months of followup was estimated through Metaprop.
Background: No previous studies have characterized a patient's experience of rheumatoid arthritis (RA) management in Greece and unmet needs may exist despite a broad range of available treatments. Therefore, we assessed quality of life (QoL), functional ability, and healthcare resource utilization in patients with established RA and receiving treatment in a tertiary care setting in Greece.
Methods: This was a prospective, observational cohort of patients aged ≥18 years, receiving any type of treatment for RA, and followed for 12 months at 7 rheumatology referral centers across mainland Greece (NCT01001182).
Background: Work disability remains a significant problem in ankylosing spondylitis (AS) and rheumatoid arthritis (RA), despite biological therapy. This study aimed to test the hypothesis that the prevalent symptom of fatigue longitudinally predicts work disability among RA and AS patients commencing etanercept.
Methods: Two observational studies, comprising RA and AS etanercept commencers, respectively, were analysed.
Introduction: Biologic agents have demonstrated efficacy in treating patients with psoriatic arthritis (PsA). Biologic agents also have an intrinsic capacity to induce an immune response in patients that could result in unwanted adverse events and/or treatment failure.
Areas Covered: In this systematic literature review, the authors document the incidence of immune responses, primarily anti-drug antibodies (ADA), to the biologic therapeutic agents currently in clinical practice for the treatment of PsA.
Dupuytren's disease (DD) is a common progressive fibroproliferative disorder causing permanent digital contracture. Proliferative myofibroblasts are thought to be the cells responsible for DD initiation and recurrence, although their source remains unknown. DD tissue has also been shown to harbor mesenchymal and hematopoietic stem cells.
View Article and Find Full Text PDFObjective: The efficacy and safety of collagenase clostridium histolyticum (CCH) in patients with Dupuytren's contracture (DC) was demonstrated in a program including two pivotal phase 3 clinical trials (CORD I and II) which included patients with a broad range of disease severity. This analysis assessed the efficacy and safety of CCH in the subpopulation of DC patients with up to two joints affected and moderate disease according to British Society of Surgery of the Hand classification. This was in support of a resubmission to the Scottish Medicines Consortium.
View Article and Find Full Text PDFArticle Synopsis
- An internet-based discrete choice experiment was conducted to determine preferences for different health states related to Dupuytren's contracture (DC), allowing researchers to quantify how this condition affects quality of life.
- The study surveyed a representative sample of UK adults about their preferences for varying severity levels of hand contractures, using detailed anatomical drawings to ensure accurate responses.
- Results from 1,745 participants provided utility estimates for affected hands, indicating that a completely affected dominant hand had a utility of 0.49, while lower severity levels showed relatively higher utilities, reflecting the varying impact of DC on daily life.
Background And Objective: Dupuytren's contractures affecting proximal interphalangeal (PIP) joints are challenging to treat. We explored the effects of collagenase Clostridium histolyticum (CCH) on PIP joint contractures after injection of an affected metacarpophalangeal (MP) joint in the same finger and after injection of an isolated PIP joint contracture.
Methods: Two patient subsets were evaluated: those with MP/PIP joints contractures in the same finger, but only the MP joint contractures were treated (Group A); and those with isolated PIP joint contractures that were treated (Group B).
Article Synopsis
- Dupuytren's disease (DD) is a common but often overlooked condition affecting the hand's fascia, leading to joint contractures, and its prevalence increases with age due to an aging global population.
- Patients with DD seek help from various healthcare providers, highlighting the need for clear guidelines on recognizing symptoms, evaluating risk factors, and understanding when to refer for treatment.
- A large European study shows that general practitioners often diagnose and refer DD cases, but there are significant differences across countries influenced by various factors, emphasizing the importance of early diagnosis and treatment for better outcomes.
Collagenase Clostridium histolyticum (CCH) is a non-surgical, efficacious therapy for Dupuytren's contracture (DC). This study evaluated the efficacy and safety of CCH in patients with previous DC surgery. Data from 12 CCH clinical trials were pooled.
View Article and Find Full Text PDFINTRODUCTION: Dupuytren's disease (DD) causes progressive digital flexion contracture and is more common in men of European descent. METHODS: Orthopaedic and plastic surgeons in 12 European countries (the Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, The Netherlands, Poland, Spain, Sweden and the UK) with >3 and <30 years experience reviewed the medical charts of five consecutive patients they had treated surgically for DD in 2008. Descriptive statistics are reported.
View Article and Find Full Text PDFArticle Synopsis
- Dupuytren's disease (DD) primarily affects European men and is mostly treated surgically, with a survey conducted among 687 surgeons in 12 European countries to understand treatment methods and factors influencing surgical choices.* -
- The survey revealed different surgical procedures used: 37% performed percutaneous needle fasciotomy, 77% fasciotomy, 95% fasciectomy, and 40% dermofasciectomy, with the complexity of the procedure affecting physical therapy prescriptions and recurrence rates.* -
- Fasciectomy emerged as the preferred procedure due to its association with lower recurrence rates compared to other methods like PNF and fasciotomy, emphasizing the importance of patient and surgical factors in treatment decisions.*